Group 1 - China Biopharmaceutical (1177.HK) saw a rise of over 3% after announcing a successful licensing agreement with Merck for its PD-1/VEGF dual antibody, expecting a $300 million milestone payment soon [1] - CSPC Pharmaceutical Group (1093.HK) increased by over 5% following the announcement of an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development of its GLP-1 receptor agonist SYH2086 [1] - Youzan (8083.HK) surged over 7% as it projected a revenue of approximately 709 to 719 million RMB for the first half of the year, a year-on-year increase of about 3.3% to 4.8%, and a net profit of 68 to 74 million RMB, marking a turnaround from a loss last year [1] Group 2 - Xingsheng International (6058.HK) rose nearly 18% after the bank announced its commitment to embrace technological transformation and explore stablecoins and AI initiatives [2] - New Oriental Education (9901.HK) fell nearly 4% after reporting a 9.4% year-on-year increase in net revenue to $1.243 billion for the fourth quarter of fiscal year 2025, but a 73.7% drop in net profit [2] - Kingdee International (0268.HK) saw a rise of over 7% as it announced a board meeting to review its interim results and potential dividend distribution [2] Group 3 - Macau gaming stocks rose, with MGM China (2282.HK) up over 4% after Macquarie raised its forecast for Macau's total gaming revenue for 2025 by 5% to 235.7 billion RMB, indicating a year-on-year growth of 4% [3] - Gold stocks in Hong Kong continued to decline, with Tongguan Gold (0340.HK) dropping over 9% for six consecutive days, as spot gold prices fell below $3,270 per ounce [4] - Kangfang Biopharma (9926.HK) rose nearly 5% after announcing the completion of the first patient dosing in a pivotal clinical trial for its PD-1/VEGF dual-specific antibody [4] Group 4 - Weishi Jiajie (0856.HK) increased by over 3% as a report indicated that its Southeast Asia business is expected to see a significant revenue increase of 74% in 2024, with net profit contributing about 51% [5] Group 5 - Meta (META.US) exceeded revenue expectations and provided strong guidance for the current quarter, leading to an after-hours increase of over 11% [6] - Microsoft (MSFT.US) reported an 18% year-on-year growth in revenue, driven by its cloud business, with Azure revenue up 34% for the full year, resulting in an after-hours increase of over 8% [6] - Wingstop (WING.US) surged by 26.85% after reporting adjusted earnings per share of $1.00 for the second quarter, exceeding analyst expectations [6] Group 6 - Several biopharmaceutical stocks surged, with Replimune (REPL.US) up 101.33% following news of regulatory changes at the FDA that may ease pressure on gene therapy and vaccine companies [7] - Marvell Technology (MRVL.US) rose 7.07% after announcing a partnership with Rebellions to provide AI systems for regional projects in Asia-Pacific and the Middle East [7] - Palo Alto Networks (PANW.US) fell 5.58% after agreeing to acquire CyberArk Software for approximately $25 billion [8]

Core Insights - The article highlights Steven Cress's role as VP of Quantitative Strategy and Market Data at Seeking Alpha, emphasizing his contributions to the platform's quantitative stock rating system and analytical tools designed to aid investors [1][2][3] Group 1: Company Overview - Seeking Alpha has developed a quantitative stock rating system that interprets data for investors, providing insights on investment directions [1] - The platform offers a systematic stock recommendation tool called Alpha Picks, aimed at helping long-term investors build a high-quality portfolio [1][2] Group 2: Leadership and Experience - Steven Cress has over 30 years of experience in equity research, quantitative strategies, and portfolio management, making him a knowledgeable figure in the investment field [4] - Prior to joining Seeking Alpha, Cress founded CressCap Investment Research, which was acquired by Seeking Alpha in 2018, and he also established the quant hedge fund Cress Capital Management [3]

周三，Astera Labs(ALAB.US)股价走高，截至发稿，该股涨超8%，报128.33美元。摩根士丹利维持该 股"买入"评级，上调目标价至125美元。 （文章来源：智通财经） ...

智通财经APP获悉，周三，Astera Labs(ALAB.US)股价走高，截至发稿，该股涨超8%，报128.33美元。 摩根士丹利维持该股"买入"评级，上调目标价至125美元。 ...

Core Viewpoint - Astera Labs (ALAB.US) shares rose over 8%, reaching $128.33, following an upgrade from Morgan Stanley, which maintained a "buy" rating and raised the target price to $125 [1] Company Summary - Astera Labs' stock price increased significantly, indicating positive market sentiment and investor confidence [1] - Morgan Stanley's upgrade and target price adjustment suggest a favorable outlook for the company's future performance [1]

Company Performance - Astera Labs, Inc. (ALAB) closed at $118.41, down 4.55% from the previous day, underperforming the S&P 500, which lost 0.3% [1] - The stock has increased by 37.19% over the past month, significantly outperforming the Computer and Technology sector's gain of 4.85% and the S&P 500's gain of 3.64% [1] Earnings Expectations - Astera Labs is expected to report earnings on August 5, 2025, with an anticipated EPS of $0.33, representing a 153.85% increase year-over-year [2] - The consensus estimate for revenue is $172.71 million, reflecting a 124.74% rise from the same quarter last year [2] Annual Forecast - For the full year, Zacks Consensus Estimates project earnings of $1.35 per share and revenue of $702.43 million, indicating increases of 60.71% and 77.25% respectively compared to the previous year [3] Analyst Estimates - Changes in analyst estimates for Astera Labs are crucial as they often indicate shifts in near-term business trends, with upward revisions suggesting positive sentiment towards the company's operations [4] Valuation Metrics - Astera Labs is currently trading with a Forward P/E ratio of 91.66, which is a premium compared to the industry average Forward P/E of 29.27 [7] - The company has a PEG ratio of 2.11, which is slightly better than the Internet - Software industry's average PEG ratio of 2.21 [7] Industry Context - The Internet - Software industry, part of the Computer and Technology sector, holds a Zacks Industry Rank of 72, placing it in the top 30% of over 250 industries [8]

The investment community will be paying close attention to the earnings performance of Astera Labs, Inc. in its upcoming release. The company is slated to reveal its earnings on August 5, 2025. It is anticipated that the company will report an EPS of $0.33, marking a 153.85% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $172.71 million, showing a 124.74% escalation compared to the year-ago quarter. For the annual period, the Z ...

Group 1 - Astera Labs, Inc. (ALAB) shares increased by 19.3% to $121.89 in the last trading session, with a higher-than-average trading volume, compared to a 9.7% gain over the past four weeks [1] - The company is experiencing strong demand for its Aries and Taurus product families, and expects accelerated shipments of Scorpio P-Series switches and Aries 6 retimers, which are based on market-leading GPUs, to enhance top-line growth [2] - Astera Labs is projected to report quarterly earnings of $0.33 per share, reflecting a year-over-year increase of 153.9%, with revenues expected to reach $172.71 million, up 124.7% from the same quarter last year [2] Group 2 - The consensus EPS estimate for Astera Labs has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - Astera Labs holds a Zacks Rank of 3 (Hold), while another company in the same industry, Exodus Movement, Inc. (EXOD), has a Zacks Rank of 4 (Sell) and saw its shares decrease by 11.8% to $33.61 in the last trading session [4][5]

Core Insights - Credo Technology Group Holding Ltd. (CRDO) and Astera Labs, Inc (ALAB) are emerging players in high-speed connectivity solutions for AI and data center infrastructure, presenting an interesting comparison for investors [1] Group 1: CRDO Overview - CRDO's fiscal 2025 revenues increased by 126% year over year to $436.8 million, with fourth-quarter revenues surging 179.7% year over year to $170 million, indicating strong adoption of its connectivity solutions [2][9] - The company is gaining market presence in Ethernet and Active Electrical Cables (AECs), with AECs showing double-digit sequential growth in the fiscal fourth quarter [3] - CRDO's integrated approach, owning the entire stack of SerDes IP, Retimer ICs, and system-level design, enhances its innovation cycles and cost efficiency [3] - The optical business, particularly for Optical Digital Signal Processors (DSPs), is expected to drive the transition to 200 gig lane speeds, with CRDO's 3-nanometer 200-gig-per-lane optical DSP port speeds reaching up to 1.6 terabits per second [4] - Operating margin expanded by 2,500 basis points in fiscal 2025, showcasing the profitability of CRDO's business model [5] - For fiscal 2026, CRDO anticipates revenues to exceed $800 million, implying over 85% year-over-year growth [6] Group 2: ALAB Overview - Astera Labs reported a 144% year-over-year revenue growth in the last quarter, driven by its Aries and Taurus product lines [7][9] - The company is focusing on portfolio expansion with new products like Scorpio Fabric Switches and optical interconnects, which are expected to enhance its market position [10] - ALAB expects second-quarter 2025 revenues between $170 million and $175 million, reflecting a 7-10% quarter-over-quarter increase [11] - Increased R&D investment may impact margins if revenue growth does not keep pace, with operating expenses projected between $73 million and $75 million in the second quarter of 2025 [12] Group 3: Market Performance and Valuation - Over the past month, CRDO and ALAB have gained 13.2% and 41.8%, respectively [15] - CRDO is trading at a forward 12-month price/sales ratio of 19.30X, while ALAB's ratio is 24.64X [16] - Analysts have significantly revised estimates for CRDO's bottom line upward in the past 60 days, while ALAB has seen marginal upward revisions [20][21] Group 4: Investment Outlook - Both CRDO and ALAB are well-positioned to benefit from the growing AI-driven data center market [22] - CRDO currently holds a Zacks Rank 1 (Strong Buy), while ALAB has a Zacks Rank 3 (Hold), suggesting CRDO may be a better investment pick at this time [22]

Most of the old guard's biggest AI-driven gains have happened. It's time for the next generation of AI stocks to step into the spotlight. There's little doubt as to the stock market's biggest winners as it relates to artificial intelligence (AI). Nvidia's (NVDA -0.46%) processors are the centerpiece of most AI data centers, while Palantir Technologies' artificial intelligence software is making the most out Nvidia's hardware. Both stocks have performed incredibly well over the course of the past couple of y ...